EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Amelioration of COVID-19 comorbid depressions via interleukin 6 with agomelatine

Yang I. Cao

Journal of Biological Regulators and Homeostatic Agents · 2025

DOI: 10.54517/jbrha3377 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Regulators and Homeostatic Agents, 2025. Verfasst von Yang I. Cao. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Existing research has found that the Spike 2 protein of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) is homogenous to the gp41 protein of the Human Immunodeficiency Virus-1. Postmortem SARS-CoV-2 patients are reported to exhibit microglial activation and expression of interleukin (IL)-1β and IL-6, corroborating with the other in vitro observations.

Methods

The translational research draws upon the phenomena from metacognition in dreams to achieve the therapeutic solution conception on Coronavirus Disease 2019 (COVID-19) vaccination-induced central nervous system (CNS) cytokine expression.

Results

Partial milestones have been achieved with cognitive-behavioral therapy in combination with agomelatine and γ-aminobutyric acid stimulation physical therapy, and the direct evidence suggests that the temporal amelioration was contributed by interleukin 6 inhibition with Agomelatine’s mechanism of action. The photic and nonphotic treatment designs have progressed in the clinical trials by the evidence-based medicine method.

Conclusions

The conservation of the circadian CNS function is the main direction for the purpose of the study design progress, and the case study for the participant with Asperger’s Syndrome indicates the correlation of migraine in autism spectrum disorder with interferon-λ.

Zitieren

APA

Cao, Y. I. (2025). Amelioration of COVID-19 comorbid depressions via interleukin 6 with agomelatine. Journal of Biological Regulators and Homeostatic Agents. https://doi.org/10.54517/jbrha3377

Vancouver

Cao YI. Amelioration of COVID-19 comorbid depressions via interleukin 6 with agomelatine. Journal of Biological Regulators and Homeostatic Agents. 2025. doi:10.54517/jbrha3377

BibTeX
@article{Cao2025,
  author = {Cao, Yang I.},
  title = {Amelioration of COVID-19 comorbid depressions via interleukin 6 with agomelatine},
  journal = {Journal of Biological Regulators and Homeostatic Agents},
  year = {2025},
  doi = {10.54517/jbrha3377}
}
Kostenlos starten →